| Ident. | Authors (with country if any) | Title |
|---|
| 000517 (2020) |
Yael Sharon [États-Unis] ; David S. Chu [États-Unis] | Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis |
| 000B10 (2019) |
Jeffrey R. Curtis [États-Unis] ; Xavier Mariette [France] ; Cécile Gaujoux-Viala [France] ; Andrew Blauvelt [États-Unis] ; Tore K. Kvien [Norvège] ; William J. Sandborn [États-Unis] ; Kevin Winthrop [États-Unis] ; Marc De Longueville [Belgique] ; Ivo Huybrechts [Belgique] ; Vivian P. Bykerk [États-Unis] | Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials |
| 000F00 (2019) |
Nuh Ata [Turquie] ; Özkan Varan [Turquie] ; Hakan Babao Lu [Turquie] ; Hasan Sati [Turquie] ; Reyhan B L C Salman [Turquie] ; Abdurrahman Tufan [Turquie] | Certolizumab Pegol Treatment in Three Patients With Takayasu Arteritis |
| 001455 (2018) |
Pavel I. Novikov [Russie] ; Ilya O. Smitienko [Russie] ; Maria V. Sokolova [Russie] ; Fatma Alibaz-Oner [Turquie] ; Sema Kaymaz-Tahra [Turquie] ; Haner Direskeneli [Turquie] ; Sergey V. Moiseev [Russie] | Certolizumab pegol in the treatment of Takayasu arteritis. |
| 001872 (2017) |
Vicente Ruiz Garcia ; Amanda Burls ; Juan B. Cabello ; Paloma Vela Casasempere ; Sylvia Bort-Marti ; José A. Bernal | Certolizumab pegol (CDP870) for rheumatoid arthritis in adults |
| 001873 (2017) |
I Igo Bermejo [Royaume-Uni] ; Matt Stevenson [Royaume-Uni] ; Rachel Archer [Royaume-Uni] ; John W. Stevens [Royaume-Uni] ; Edward Goka [Royaume-Uni] ; Mark Clowes [Royaume-Uni] ; David L. Scott [Royaume-Uni] ; Adam Young [Royaume-Uni] | Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. |
| 001933 (2017) |
Michael E. Weinblatt ; Clifton O. Bingham ; Gerd-Rüdiger Burmester ; Vivian P. Bykerk ; Daniel E. Furst ; Xavier Mariette ; Désirée Van Der Heijde ; Ronald Van Vollenhoven ; Brenda Vanlunen ; Cécile Ecoffet ; Christopher Cioffi ; Paul Emery | A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis |
| 001C16 (2016) |
Matt Stevenson [Royaume-Uni] ; Rachel Archer [Royaume-Uni] ; Jon Tosh [Royaume-Uni] ; Emma Simpson [Royaume-Uni] ; Emma Everson-Hock [Royaume-Uni] ; John Stevens [Royaume-Uni] ; Monica Hernandez-Alava [Royaume-Uni] ; Suzy Paisley [Royaume-Uni] ; Kath Dickinson [Royaume-Uni] ; David Scott [Royaume-Uni] ; Adam Young [Royaume-Uni] ; Allan Wailoo [Royaume-Uni] | Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. |
| 001C81 (2016) |
Matt Stevenson [Royaume-Uni] ; Rachel Archer [Royaume-Uni] ; Jon Tosh [Royaume-Uni] ; Emma Simpson [Royaume-Uni] ; Emma Everson-Hock [Royaume-Uni] ; John Stevens [Royaume-Uni] ; Monica Hernandez-Alava [Royaume-Uni] ; Suzy Paisley [Royaume-Uni] ; Kath Dickinson [Royaume-Uni] ; David Scott [Royaume-Uni] ; Adam Young [Royaume-Uni] ; Allan Wailoo [Royaume-Uni] | Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. |
| 001E42 (2015) |
Michael E. Weinblatt [États-Unis] ; Roy Fleischmann [États-Unis] ; Ronald F. Van Vollenhoven [Suède] ; Paul Emery [Royaume-Uni] ; Tom Wj Huizinga [Pays-Bas] ; Maurizio Cutolo [Italie] ; Désirée Van Der Heijde [Pays-Bas] ; Benjamin Duncan [États-Unis] ; Owen Davies [Belgique] ; Kristel Luijtens [États-Unis] ; Maxime Dougados [France] | Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population |
| 002488 (2014) |
J S Smolen [Autriche] ; P. Emery [Royaume-Uni] ; G F Ferraccioli ; W. Samborski [Pologne] ; F. Berenbaum [France] ; O R Davies [Belgique] ; W. Koetse [États-Unis] ; O. Purcaru [Belgique] ; B. Bennett [États-Unis] ; H. Burkhardt [Allemagne] | Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial |
| 002653 (2013) |
V P Bykerk [États-Unis] ; J. Cush [États-Unis] ; K. Winthrop [États-Unis] ; L. Calabrese [États-Unis] ; O. Lortholary [France] ; M. De Longueville [Belgique] ; R. Van Vollenhoven [Suède] ; X. Mariette [France] | Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials |
| 002745 (2013) |
Edward Keystone [Canada] ; Robert Landewé [Pays-Bas] ; Ronald Van Vollenhoven [Suède] ; Bernard Combe [France] ; Vibeke Strand [États-Unis] ; Philip Mease [États-Unis] ; Laura Shaughnessy [États-Unis] ; Brenda Vanlunen [États-Unis] ; Désirée Van Der Heijde [Pays-Bas] | Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension |
| 002E68 (2013) |
M. Clowse ; D. Wolf [États-Unis] ; F. Förger [Suisse] ; C. Stach [Allemagne] ; G. Kosutic [États-Unis] ; S. Williams [États-Unis] ; I. Terpstra [Belgique] ; U. Mahadevan [États-Unis] | FRI0176 Outcomes of pregnancy in subjects exposed to certolizumab pegol |
| 002E77 (2013) |
T. Baker [Royaume-Uni] ; L. Kevorkian [Royaume-Uni] ; A. Nesbitt [Royaume-Uni] | FRI0162 Investigation into the binding affinity of certolizumab pegol to fcrn and functional consequences for fcrn-mediated transcytosis: comparison to infliximab, adalimumab and etanercept |
| 002E80 (2013) |
S. Perrier D Auterive [Belgique] ; S. Kesseler [Belgique] ; P. Ruggeri [Belgique] ; M. Timmermans [Belgique] ; O. Gaspard [Belgique] ; T. Kumke [Allemagne] ; G. Parker [Royaume-Uni] | FRI0160 Certolizumab PEGOL did not result in a decrease in semen quality in healthy volunteers: Results from a phase 1 study |
| 003204 (2013) |
M. Schiff [États-Unis] ; K. Luijtens [Belgique] ; O. Davies [Belgique] ; Y. Yazici [États-Unis] | AB0317 Association of ACR clinical responses with CDAI (clinical disease activity index) and RAPID3 (routine assessment of patient index data 3) indices of disease activity in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate |
| 003239 (2013) |
Y. Tanaka ; K. Yamamoto [Japon] ; T. Takeuchi ; H. Yamanaka [Japon] ; N. Ishiguro ; K. Eguchi ; A. Watanabe [Japon] ; H. Origasa ; T. Okamoto ; T. Shoji ; N. Miyasaka [Japon] ; T. Koike [Japon] | AB0294 Long-term comprehensive disease control with certolizumab pegol regardless of concomitant dmards: results from the japanese cohort |
| 003B12 (2011) |
Ines Zidi [Tunisie, Arabie saoudite] ; Wissem Mnif [Tunisie] ; Aicha Bouaziz [Tunisie] ; Nidhal Ben Amor [Tunisie, Arabie saoudite] | Certolizumab pegol therapy of rheumatoid arthritis: Overview |
| 003B94 (2011) |
Robert Launois [France] ; Bernard Avouac ; Francis Berenbaum ; Olivier Blin ; Isabelle Bru ; Bruno Fautrel ; Jean-Michel Joubert ; Jean Sibilia ; Bernard Combe | Comparison of Certolizumab Pegol with Other Anticytokine Agents for Treatment of Rheumatoid Arthritis: A Multiple-treatment Bayesian Metaanalysis |
| 004014 (2009) |
Margaret Hy [Royaume-Uni] ; Ernest Hs Choy [Royaume-Uni] | Certolizumab pegol: a new option for rheumatoid arthritis |
